[18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0

Cristina Nanni; Lucia Zanoni; Tore Bach-Gansmo; Heikki Minn; Frode Willoch; Trond Velde Bogsrud; Ephraim Parent Edward; Bital Savir-Baruch; Eugene Teoh; Fenton Ingram; Stefano Fanti; David M Schuster

doi:10.1007/s00259-019-04614-y

[¹⁸F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0

Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):579-591. doi: 10.1007/s00259-019-04614-y. Epub 2019 Dec 11.

Authors

Affiliations

¹ MNM AOU S.Orsola-Malpighi, Bologna, Italy. cristina.nanni@aosp.bo.it.
² MNM AOU S.Orsola-Malpighi, Bologna, Italy.
³ Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
⁴ Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland.
⁵ PET-Centre, University Hospital of North Norway, Tromso, Norway.
⁶ Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark.
⁷ Department of Radiology and Imaging Services, Emory University, Atlanta, GA, USA.
⁸ Division of Nuclear Medicine, Department of Radiology, Loyola University Medical Center, Maywood, IL, USA.
⁹ Department of Oncology, University of Oxford, Oxford, UK.
¹⁰ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA.

PMID: 31822959
DOI: 10.1007/s00259-019-04614-y

Abstract

The aim of this guideline is to provide standards for the recommendation, performance, interpretation, and reporting of [¹⁸F]Fluciclovine PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of [¹⁸F]Fluciclovine PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.

Keywords: Guideline; PET; Prostate cancer; Restaging; Staging; [18F]Fluciclovine.

MeSH terms

Cyclobutanes*
Humans
Male
Positron Emission Tomography Computed Tomography
Prostatic Neoplasms* / diagnostic imaging

Substances

Cyclobutanes